Option chain shows key data for Soligenix's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Soligenix.

Soligenix (NASDAQ:SNGX) Stock, Option Chain

Soligenix

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Screenshot 2024-12-16 at 6.43.37 PM

Biotech

General

SNGX

Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL

News

Health Care

Market-Moving Exclusives

Exclusives

Soligenix opens enrollment for the Phase 3 FLASH2 study of HyBryte in early-stage CTCL, aiming to confirm extended treatment efficacy over 18 weeks.

EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer

Screenshot 2024-11-26 at 8.32.36 PM

Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs

Soligenix Inc

On Monday, Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) said it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL).
The confirmatory Phase 3 study, FLASH2, builds on the previous statistically significant Phase 3 (FLASH) study, as well as a recent comparative study (HPN-CTCL-04) and an ongoing investigator-initiated study, each further supporting the design of the FLASH2 clinical trial.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41968331/soligenix-kickstarts-dusquetide-mid-stage-study-for-patients-with-inflamed-blood-vessels" rel="noreferrer noopener">Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels</a>
The FLASH2 study is expected to enroll patients in the U.S. and Europe, and a formal interim analysis is anticipated early in 2026.
The company looks forward to providing periodic updates on the trial's progress in 2025
FLASH2 will enroll approximately 80 subjects with early-stage CTCL, a group of rare blood cancers that affect the skin.
The study replicates the double-blind, placebo-controlled design used in the first Phase 3 FLASH study, which consisted of three 6-week treatment cycles (18 weeks total). The primary efficacy assessment occurred at the end of the initial 6-week cycle (Cycle 1).
However, this second study extends to 18 weeks of continuous treatment (no "between-cycle" treatment breaks), with the primary endpoint assessment occurring at the end of the 18-week timepoint.
In the first Phase 3 study, a treatment response of 49% (p&lt;0.0001 vs patients receiving placebo in Cycle 1) was observed in patients completing 18 weeks (3 cycles) of therapy.
The extended treatment for a continuous 18 weeks in a single cycle is expected to statistically demonstrate the effect of HyBryte over a more prolonged, "real world" treatment course.
In July, Soligenix shared an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte treatment for up to 12 months in patients with <a href="https://www.benzinga.com/general/biotech/24/07/39692597/nano-cap-soligenix-stock-surges-over-200-on-tuesday-heres-why" target="_blank" rel="noreferrer noopener">early-stage CTCL</a>.
Price Action: SNGX stock closed at $3.14 on Friday.

EXCLUSIVE: Soligenix Tells Benzinga Co. Initiates Confirmatory Phase III Trial Of HyBryte For The Treatment Of Cutaneous T-Cell Lymphoma

Soligenix Announced That Analysis Of The Post-treatment Data From The Open-label Study Comparing HyBryte (Synthetic Hypericin) To Valchlor (Mechlorethamine) Has Demonstrated Continued Improvement In HyBryte-treated Patients And Their Individual Lesions Even After Stopping Treatment

Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024

On Thursday, Soligenix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) opened patient enrollment for its DUS-AUBD-01 Phase 2 study evaluating SGX945 (dusquetide) for Behçet's Disease, an inflammatory disorder of the blood vessels (vasculitis).
The company looks forward to completing enrollment and announcing study results in the first half of 2025.
The pilot clinical trial of SGX945 will be an open-label study that will enroll approximately 25 patients aged 18 years or older with mild to moderate Behçet's Disease and active oral and/or genital ulcers.
Patients will receive SGX945 as a twice-weekly 4-minute intravenous (IV) infusion for 4 weeks, followed by 4 weeks of follow-up.
Efficacy endpoints will include the extent of lesion clearance, timeline to lesion clearance, and patient reported quality of life assessments.&nbsp;&nbsp;
Dusquetide, the active ingredient in SGX945 (Behçet's Disease) and <a target="_blank" href="https://www.soligenix.com/pipeline-programs/sgx942-treatment-for-oral-mucositis/" rel="noreferrer noopener">SGX942 (oral mucositis)</a>, is an innate defense regulator (IDR), a new class of short, synthetic peptides.
Dusquetide has demonstrated safety and tolerability in a Phase 1 study in 84 healthy human volunteers.
In Phase 2 and 3 clinical studies with dusquetide in over 350 subjects with oral mucositis due to chemoradiation therapy for head and neck cancer, positive efficacy results were demonstrated, including potential long-term <a target="_blank" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470438/" rel="noreferrer noopener">ancillary benefits</a>.
There are approximately 18,000 known cases of Behçet's Disease in the U.S., 350,000 in Turkey, and over 50,000 in Europe. There are as many as 1 million people worldwide living with Behçet's Disease.
In July, The Princeton, New Jersey-based company announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended Hybryte treatment for up to 12 months in patients with early-stage cutaneous&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39692597/nano-cap-soligenix-stock-surges-over-200-on-tuesday-heres-why" rel="noreferrer noopener">T-cell lymphoma (CTCL)</a>.
Patients have responded positively to HyBryte therapy. Three of the four subjects who have completed at least 12 weeks of therapy already achieved "Treatment Success."
Price Action: At the last check on Thursday, SNGX stock traded higher by 1.10% to $3.67 premarket.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41950702/boeing-reportedly-plans-furloughs-whats-going-on" target="_blank" rel="noreferrer noopener">Boeing Reportedly Plans Furloughs: What's Going On</a></li>
</ul>

Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels

Soligenix Initiates A Phase 2 Clinical Trial Of SGX945 For The Treatment Of Behçet's Disease; Says Study DUS-AUBD-01 Opens Patient Enrollment

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares increased by 106.6% to $2.81 during Friday's after-market session. The company's market cap stands at $5.2 million. </li>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) shares rose 8.36% to $3.37. The company's market cap stands at $114.2 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock moved upwards by 6.25% to $1.02. The company's market cap stands at $6.0 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock increased by 6.18% to $3.26. The market value of their outstanding shares is at $2.4 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock increased by 5.45% to $1.16. The market value of their outstanding shares is at $63.9 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock moved upwards by 5.0% to $0.39. The market value of their outstanding shares is at $6.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 10.1% to $0.06 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 10.07% to $0.39. The market value of their outstanding shares is at $2.8 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares fell 6.96% to $3.56. The company's market cap stands at $8.1 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock declined by 6.67% to $2.38. The market value of their outstanding shares is at $46.9 million. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares declined by 6.11% to $2.77. The market value of their outstanding shares is at $7.7 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) stock decreased by 5.13% to $1.85. The company's market cap stands at $45.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BMRA

Envoy Medical, Inc. - Class A Common Stock

COCH

FRES

KDLY

NUWE

OMGA

PPBT

SINT

VCNX

VERO

12 Health Care Stocks Moving In Friday's After-Market Session

Soligenix Says Hong Kong Patent Office Has Granted Patent Entitled 'Systems And Methods For Producing Synthetic Hypericin'

<h3>Gainers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) shares increased by 17.4% to $0.82 during Monday's after-market session. The company's market cap stands at $25.3 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares rose 5.92% to $0.42. The market value of their outstanding shares is at $3.6 million. </li>
<li>Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) shares increased by 5.91% to $46.55. The company's market cap stands at $5.5 billion. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock increased by 5.83% to $0.26. The company's market cap stands at $1.6 million. </li>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares increased by 5.22% to $1.41. The company's market cap stands at $60.1 million. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) stock increased by 4.97% to $13.07. The market value of their outstanding shares is at $784.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares decreased by 8.7% to $0.12 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) stock declined by 7.6% to $2.31. The company's market cap stands at $1.9 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares fell 6.62% to $3.95. The market value of their outstanding shares is at $9.0 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock declined by 6.39% to $0.25. The market value of their outstanding shares is at $5.5 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock decreased by 5.43% to $1.22. The market value of their outstanding shares is at $15.6 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares decreased by 5.42% to $1.31. The market value of their outstanding shares is at $78.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IMNM

KAPA

LGMK

MYNZ

OGEN

TIVC

TRVN

VINC

VRCA

12 Health Care Stocks Moving In Monday's After-Market Session

Macro Notification

GOVX

HHS Says CDC To Issue Level 3 Travel Health Notice For Rwanda On Oct 7; Rwanda Has Reported 49 Cases And 12 Deaths From Marburg Virus As Of Oct 6; CDC To Begin Public Health Entry Screening For Travelers Entering US From Rwanda Starting Week Of Oct 14; Level 3 Notice Recommends Reconsideration Of Nonessential Travel To Rwanda

Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,&nbsp;announced today that&nbsp;two of its lead investigators are presenting findings from recent additional, supportive trials with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4270389-1&amp;h=1804281992&amp;u=https%3A%2F%2Fwww.hybryte.com%2F&amp;a=HyBryte%E2%84%A2">HyBryte&#x2122;</a>&nbsp;(synthetic hypericin) in the treatment of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4270389-1&amp;h=4183932232&amp;u=https%3A%2F%2Fwww.soligenix.com%2Four-focus%2Fcutaneous-t-cell-lymphoma%2F&amp;a=cutaneous+T-cell+lymphoma">cutaneous T-cell lymphoma</a> (CTCL). The presentations will occur at the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumour Group Annual Meeting in Lausanne, Switzerland on October 9-11, 2024.&nbsp;Dr. Ellen Kim, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of the&nbsp;University of Pennsylvania, will present a poster with expanded preliminary results from the investigator-initiated study (RW-HPN-MF-01) she is leading at the University of Pennsylvania. Dr. Brian Poligone, Director of the Rochester Skin Lymphoma Medical Group, will give an oral presentation on recent results from two expanded treatment studies (HPN-CTCL-02 and HPN-CTCL-04) conducted at the Rochester Skin Lymphoma Medical Group.

Soligenix to Present New Findings on HyBryte for Treating T-Cell Lymphoma at EORTC Meeting

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares moved upwards by 33.5% to $1.66 during Thursday's regular session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares rose 31.53% to $1.46. The company's market cap stands at $62.2 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock rose 30.98% to $1.99. The company's market cap stands at $3.5 million. </li>
<li>OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) stock increased by 20.96% to $3.52. The company's market cap stands at $73.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock rose 20.84% to $0.6. The market value of their outstanding shares is at $10.3 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 17.26% to $0.86. The company's market cap stands at $51.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares decreased by 21.5% to $1.13 during Thursday's regular session. The market value of their outstanding shares is at $1.8 million. </li>
<li>AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) stock declined by 17.13% to $6.34. The company's market cap stands at $257.6 million. The company's, Q1 earnings came out today. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock fell 16.64% to $4.06. The company's market cap stands at $9.2 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 15.7% to $1.45. The market value of their outstanding shares is at $3.4 million. </li>
<li>BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) shares declined by 14.01% to $2.21. The market value of their outstanding shares is at $89.0 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 12.85% to $1.96. The market value of their outstanding shares is at $10.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANGO

BBLG

BYSI

GCTK

OSTX

RNAZ

TNFA

TOVX

WINT

12 Health Care Stocks Moving In Thursday's Intraday Session

WHO Chief Says Assesses The Risk Of Marburg Virus Outbreak As Very High At The National Level, High At The Regional Level, And Low At The Global Level

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares moved upwards by 53.2% to $1.9 during Thursday's pre-market session. The company's market cap stands at $2.5 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares moved upwards by 22.1% to $0.12. The company's market cap stands at $11.1 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock moved upwards by 14.0% to $0.23. The market value of their outstanding shares is at $4.1 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares increased by 13.45% to $0.42. The company's market cap stands at $4.1 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares rose 12.01% to $0.99. The company's market cap stands at $2.5 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares rose 10.69% to $8.9. The market value of their outstanding shares is at $11.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock decreased by 16.0% to $1.21 during Thursday's pre-market session. The company's market cap stands at $1.9 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock fell 14.79% to $4.15. The market value of their outstanding shares is at $9.4 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares decreased by 11.59% to $0.39. The market value of their outstanding shares is at $11.4 million. </li>
<li>ALT5 Sigma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTS#NASDAQ">ALTS</a>) stock declined by 11.3% to $1.58. The market value of their outstanding shares is at $21.3 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock decreased by 9.63% to $4.44. The company's market cap stands at $4.6 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) stock decreased by 9.08% to $17.23. The company's market cap stands at $3.7 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALTS

BPTH

Hims & Hers Health, Inc. Class A Common Stock

HIMS

KTTA

KZIA

NDRA

RDHL

SYRA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Soligenix and Sterling are currently working to transfer and optimize the manufacturing processes and analytics to enable GMP manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.

Soligenix Establishes Partnership Agreement With Sterling Pharma Solutions To Optimize, Implement A Commercially Viable, Scalable Production Technology For Synthetic Hypericin

Shares of Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) fell sharply in today's pre-market trading <a href="https://www.benzinga.com/news/earnings/24/10/41151280/levi-strauss-co-stock-falls-after-mixed-q3-results-eps-beat-revenues-miss">following third-quarter results</a>.
Levi Strauss posted better-than-expected earnings for its third quarter, while sales missed estimates. The company said it sees fiscal year 2024 adjusted earnings at a mid-point of between $1.17 and $1.27 per share, versus the $1.25 estimate.
Levi Strauss shares dipped 10.6% to $18.80 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares rose 47.3% to $0.1399 in pre-market trading after dipping around 10% on Wednesday.</li>
<li>MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) rose 42% to $0.4399 in pre-market trading after gaining 22% on Wednesday.</li>
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) gained 30.4% to $17.46 in pre-market trading after jumping around 99% on Wednesday.</li>
<li>Mynaric AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) shares rose 11.2% to $1.49 in pre-market trading. Mynaric secured $5.5 million bridge loan and receipt of $5.5 million manufacturing readiness milestone payment to meet immediate working capital needs.</li>
<li>AMTD Digital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) rose 10% to $4.30 in pre-market trading after surging 22% on Wednesday.</li>
<li>Flux Power Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>) gained 8.8% to $3.20 in pre-market trading.</li>
<li>AirNet Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTX#NASDAQ">ANTX</a>) shares gained 7.9% to $0.4056 in pre-market trading after surging 17% on Wednesday.</li>
<li>Graphex Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#NYSE">GRFX</a>) shares surged 7.8% to $0.2297 in pre-market trading after jumping around 20% on Wednesday.</li>
<li>VCI Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) shares jumped 7.7% to $0.1418 in pre-market trading after dipping around 18% on Wednesday. VCI Global recently secured new investment commitment of $30 million from Alumni Capital.</li>
<li>ENDRA Life Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares gained 6.2% to $0.2148 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>EON Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EONR#NYSE">EONR</a>) shares dipped 17.7% to $1.35 in pre-market trading after falling 8% on Wednesday.</li>
<li>Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) fell 17.7% to $4.00 in today's pre-market trading. Soligenix shares jumped around 28% on Wednesday following a report suggesting that police cordoned off two tracks at a Germany train station due to fears that a traveler was infected by the Marburg virus. The company, in April 2024, announced that the FDA granted it an orphan drug designation for the active ingredient in MarVax.</li>
<li>Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) fell 17.8% to $3.60 in pre-market trading after jumping 29% on Wednesday.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) shares fell 17.7% to $0.2830 in pre-market trading after declining 12% on Wednesday. MicroCloud Hologram announced results of its 2024 annual general meeting of the shareholders.</li>
<li>Kaixin Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) fell 17.4% to $0.2821 in pre-market trading after jumping 172% on Wednesday.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) declined 14.6% to $0.6550 in pre-market trading after jumping around 64% on Wednesday.</li>
<li>ZW Data Action Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNET#NASDAQ">CNET</a>) shares declined 14.3% to $2.33 in pre-market trading after dipping around 18% on Wednesday.</li>
<li>Youdao, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAO#NYSE">DAO</a>) shares fell 9.2% to $5.40 in pre-market trading after jumping around 38% on Wednesday.</li>
<li>CNFinance Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNF#NASDAQ">CNF</a>) shares fell 9% to $2.25 in pre-market trading after jumping around 27% on Wednesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41156151/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

ANTX

CNET

EONR

FLUX

GRFX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

KXIN

LEVI

MLGO

MYNA

VCIG

WHLR

Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock rose 31.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $9.6 million. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares rose 30.07% to $1.73. The market value of their outstanding shares is at $5.6 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock rose 8.83% to $0.28. </li>
<li>Eagle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) shares increased by 7.94% to $2.31. The market value of their outstanding shares is at $29.9 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock moved upwards by 7.89% to $1.64. The company's market cap stands at $2.9 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares increased by 7.36% to $0.1. The market value of their outstanding shares is at $9.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock declined by 8.6% to $4.45 during Wednesday's after-market session. The company's market cap stands at $10.1 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares fell 6.34% to $0.28. The company's market cap stands at $2.1 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock decreased by 5.3% to $1.25. The company's market cap stands at $16.0 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock declined by 4.77% to $1.0. The market value of their outstanding shares is at $226.2 million. </li>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) shares fell 4.75% to $2.21. The market value of their outstanding shares is at $105.9 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares fell 4.66% to $1.64. The market value of their outstanding shares is at $3.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CPHI

CTCX

EGRX

GOSS

GUTS

PCSA

12 Health Care Stocks Moving In Wednesday's After-Market Session

Soligenix Shares Resumed Trade

WIIM

Soligenix shares are trading higher following a report suggesting that police cordoned off two tracks at a Germany train station due to fears that a traveler was infected by the Marburg virus. The company, in April 2024, announced that the FDA granted it an orphan drug designation for the active ingredient in MarVax.

Soligenix Shares Halted On Circuit Breaker To The Upside, Stock Now Up 22.1%

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Wednesday as we break down all of the biggest news this morning!



Moving stocks are new contracts and agreements, ongoing rallies, retreats from rallies and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Ampco-Pittsburgh (NYSE:<a href="https://investorplace.com/stock-quotes/ap-stock-quote/">AP</a>) stock is rocketing more than 75% on <a href="https://www.nasdaq.com/press-release/ampco-pittsburgh-subsidiaries-announce-commercial-contract-wins-and-strong-growth">commercial contract wins and backlog news</a>.</li>



<li>Vivopower (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvpr-stock-quote/">VVPR</a>) shares are soaring over 54% on a <a href="https://www.nasdaq.com/press-release/vivopower-secures-extension-us-34m-loan-financing-facility-agreement-2024-07-09">new extended loan facility agreement</a>.</li>



<li>Seelos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/seel-stock-quote/">SEEL</a>) stock is surging more than 33% alongside heavy pre-market trading.</li>



<li>Naas Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/naas-stock-quote/">NAAS</a>) shares are rising over 27% with strong early morning trading.</li>



<li>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) stock is increasing more than 25% as it <a href="https://investorplace.com/2024/07/why-is-soligenix-sngx-stock-up-296-today/">continues to rally</a>.</li>



<li>Cumulus Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmls-stock-quote/">CMLS</a>) shares are gaining over 19% without any clear news this morning.</li>



<li>Smart for Life (NASDAQ:<a href="https://investorplace.com/stock-quotes/smfl-stock-quote/">SMFL</a>) stock is climbing more than 18% after <a href="https://www.nasdaq.com/press-release/smart-life-announces-appointment-jessica-walters-chief-marketing-officer-2024-07-09">naming a new Chief Marketing Officer</a>.</li>



<li>A2Z Smart Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/az-stock-quote/">AZ</a>) shares are heading over 15% higher as they continue a recent rally.</li>



<li>Aehr Test Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/aehr-stock-quote/">AEHR</a>) stock is jumping more than 15% <a href="https://seekingalpha.com/news/4123175-aehr-test-systems-stock-up-14-after-raises-fy24-revenue-guidance-above-estimates">after increasing its guidance</a>.</li>



<li>Neuronetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/stim-stock-quote/">STIM</a>) shares are up over 13% despite a lack of news on Wednesday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>LegalZoom.com (NASDAQ:<a href="https://investorplace.com/stock-quotes/lz-stock-quote/">LZ</a>) stock is diving 26% after <a href="https://www.nasdaq.com/press-release/legalzoom-announces-leadership-transition-2024-07-09">announcing leadership changes</a>.</li>



<li>MariaDB (NYSE:<a href="https://investorplace.com/stock-quotes/mrdb-stock-quote/">MRDB</a>) shares are tumbling more than 25% without any apparent news this morning.</li>



<li>AFC Gamma (NASDAQ:<a href="https://investorplace.com/stock-quotes/afcg-stock-quote/">AFCG</a>) stock is taking an over 20% beating on Wednesday morning.</li>



<li>Zapp Electric Vehicles (NASDAQ:<a href="https://investorplace.com/stock-quotes/zapp-stock-quote/">ZAPP</a>) shares are retreating more than 17% <a href="https://www.marketwatch.com/amp/story/zapp-electric-shares-jump-68-after-june-china-auto-sales-report-160c0c60">following a rally yesterday</a>.</li>



<li>LogicMark (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgmk-stock-quote/">LGMK</a>) stock is falling over 16% after rallying on Tuesday.</li>



<li>Sify Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sify-stock-quote/">SIFY</a>) shares are dropping more than 16% today.</li>



<li>Stardust Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdst-stock-quote/">SDST</a>) stock is decreasing over 15% <a href="https://markets.businessinsider.com/news/stocks/stardust-power-jumps-45-in-pre-market-ahead-of-nasdaq-debut-1033539375">after rallying with its debut</a>.</li>



<li>Top KingWin (NASDAQ:<a href="https://investorplace.com/stock-quotes/tcjh-stock-quote/">TCJH</a>) shares are slipping more than 14% this morning.</li>



<li>Applied DNA Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/apdn-stock-quote/">APDN</a>) stock is dipping over 14% today.</li>



<li>Connexa Sports Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/yyai-stock-quote/">YYAI</a>) shares close out our pre-market stock movers down more than 13% on Wednesday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-10th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
While investing in the best&nbsp;<a href="https://investorplace.com/stock-types/blue-chip-stocks/" target="_blank">blue chip stocks</a>&nbsp;to anchor your portfolio is always a good idea, I am always looking to diversify. A good way to do that is to invest in lesser-known but quality stocks under $10.



Lower-priced stocks have the advantage of being affordable so that you can buy more shares with less money. It&rsquo;s much cheaper to buy 100 shares of a $5 stock than to buy the same number of shares of an equity that cost $100 or more, right?



And these lower-priced stocks still can outperform the market. While the risks are higher, the rewards can be substantial, offering a tempting opportunity for investors willing to take on some level of risk.



I always suggest using the Portfolio Grader to help find the best stocks under $10. In fact, using a stock screening tool is essential in an exercise such as this.



Why? Because there are over&nbsp;<a href="https://money.usnews.com/investing/stocks/search?price-min=0&amp;price-max=10" target="_blank">2,100 stocks</a>&nbsp;on the market today are&nbsp;priced at $10 or less. No one can identify all of the best-performing stocks &ndash; or those that have the potential to perform &ndash; without using a screener like the Portfolio Grader to narrow the field.



The Portfolio Grader evaluates stocks based on various measurements, including earnings performance, growth, analyst sentiment, and momentum. The stocks under $10 on this list all score well enough to get at least a &ldquo;B&rdquo; rating in the Portfolio Grader tool.



<h2>Faraday Future Intelligent Electric (FFIE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/ffie1600-1-300x169.png" alt="Person holding cellphone with logo of electric vehicle company Faraday Future Inc. (FFIE) on screen in front of business webpage. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>Faraday Future Intelligent Electric (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) designs, manufactures and sells electric vehicles and related products. The California company operates in the United States and China.



The company has gotten into some hot water with Nasdaq and its listing requirements because the stock is less than $1 &ndash; it has until Aug. 31 to get the stock price up &ndash; and for not always promptly filing financial reports. 



Those are red flags for sure, so already you know FFIE stock is a speculative play.



Although revenue in 2023 was only $800,000, it was the company&rsquo;s first year of revenue, as it&rsquo;s still very much a startup. Faraday delivered its first-ever vehicles in the third quarter of the year.



However, Faraday also has some interesting things in the works, as outlined in its <a href="https://investors.ff.com/news-releases/news-release-details/faraday-future-hosts-investor-community-day-and-highlights">July 20 Investor Day event</a>. Highlights included a look at the All-Ability aiHypercar, its user ecosystem, and the company&rsquo;s Auto Industry Bridge strategy.



The company raised the idea of launching a second, lower-priced automotive brand. &ldquo;A second brand could strike in the mass market with volume production, bringing everyone the &lsquo;AI car of the future&rsquo; and the &lsquo;AI car of the people&rsquo;. 



We are preparing to launch the Bridge and second brand strategies in a future event where we will share more details and our progress. We are hopeful to set sail together in the blue ocean market with potential partners,&rdquo;&nbsp;founder YT Jia said.



The company scheduled a July 31 shareholder vote that includes a proposal for a 1-for-40 reverse stock split to maintain its Nasdaq compliance. For now, FFIE stock gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>SoundHound AI (SOUN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/soun1600-1-300x169.png" alt="In this photo illustration, the SoundHound logo seen displayed on a smartphone. SOUN stock"><div>Source: rafapress / Shutterstock.com</div></div>SoundHound AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) is an up-and-coming technology company that is using artificial intelligence and machine learning to create products that recognize and respond to verbal prompts.



SoundHound&rsquo;s platform is used by restaurants to <a href="https://investors.soundhound.com/news-releases/news-release-details/beef-o-bradys-rolls-out-soundhounds-advanced-voice-ai-ordering">automate food ordering</a>, reducing employee costs. Through its Dynamic Interaction platform, customers can verbally place complicated orders at a kiosk and pay without the intervention of an employee.



Another interesting use of SoundHound&rsquo;s platform is its employee training. Inexperienced workers can use SoundHound to ask questions about a process and SoundHound&rsquo;s AI will answer intelligently and walk the employee through the proper steps.



SoundHound also has a product that has a <a href="https://investors.soundhound.com/news-releases/news-release-details/soundhound-chat-ai-launches-peugeot-opel-and-vauxhall-vehicles">Chat AI product</a> &ndash; integrated with ChatGPT &ndash; that can manage navigation, advise about the weather or tell stories to bored children in the back seat.



I also like that SoundHound is shoring up its financial position. The company <a href="https://finance.yahoo.com/news/soundhound-ai-announces-early-debt-130000956.html">announced</a> that it reached an agreement with lenders to repay $100 million in outstanding debt. Once that&rsquo;s done, SoundHound will have zero debt and a cash balance of $180 million.



<a href="https://investors.soundhound.com/news-releases/news-release-details/soundhound-ai-reports-73-q1-revenue-growth-116-million-first">Revenue in the first quarter</a>&nbsp;was $11.6 million, up 73% from a year ago. And with a subscription and booking backlog of $682 million, up 80% from just a year ago, I think SoundHound will start turning a profit soon.



SOUN stock gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Kazia Therapeutics (KZIA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) is an Australian oncology company that&rsquo;s developing therapies for brain, liver and renal cancers.



The company&rsquo;s lead program is paxalisib, which is currently in Phase 3 trials as a treatment for glioblastoma, which is an aggressive form of brain cancer. Paxalisib is also in Phase 2 trials as a treatment for childhood brain cancers, brain metastases, and non-Hodgkin&rsquo;s lymphoma.



The stock had massive gains this month when it announced <a href="https://investorplace.com/2024/07/why-is-kazia-therapeutics-kzia-stock-up-300-today/">positive results</a> for paxalisib&rsquo;s glioblastoma trial. The company reported that patients who received paxalisib had a median overall survival period of 14.77 months, compared to 13.84 months for patients who did not receive the drug.



In a prespecified secondary analysis, the survival period for paxalisib patients was 15.54 months compared to 11.89 months for patients who did not take the drug.



Investing in biotech and pharma stocks can be very challenging because there&rsquo;s a lot of research &ndash; and a lot of expense &ndash; before a drug can even go to regulators for possible approval. But Kazia&rsquo;s work appears to be promising, and that&rsquo;s driving the momentum of KZIA stock right now.



Kazia stock is up 40% over the last month, and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Koss (KOSS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/koss1600-300x169.png" alt="Koss Porta Pro Wireless headphones on a round case like on your head on a white background with reflection"><div>Source: PhotOleh / Shutterstock.com</div></div>Koss (NASDAQ:<a href="https://investorplace.com/stock-quotes/koss-stock-quote/">KOSS</a>) is a manufacturer of headphones and accessories such as earbuds, electrostatic headphones and audio products for health care and education.



The company has been around for more than 60 years and came to renewed prominence in recent years as a popular meme stock. The meme factor makes Koss a volatile stock &ndash; shares jumped <a href="https://investorplace.com/2024/07/koss-stock-alert-koss-surges-90-on-renewed-meme-interest/">90% earlier this month</a> on speculative short-seller interest.



Earnings for the company&rsquo;s fiscal third quarter (ending March 31) showed weakening performance. Sales of $2.6 million was down from $3.3 million in the same quarter a year ago. Profits of $841,000 were down from $1.3 million on a year-over-year basis.



Koss is purely a meme stock play and should be treated with a lot of caution. If the stock jumps again &ndash; and odds are that it will &ndash; it would be wise to take profits at the peak.



KOSS stock is up 171% this year and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>VivoPower International (VVPR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/05/electric-vehicle-ev-stocks-charging-black-neon-1600-300x169.jpg" alt="Electric car backlit by cyan blue neon light next to EV charger with cyan blue light and lightning bolt symbol, all against a black background. ev stocks to buy"><div>Source: shutterstock.com/JLStock</div></div>VivoPower International (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvpr-stock-quote/">VVPR</a>) is an international battery technology and electric vehicle services company headquartered in the U.K. The company also operates in Australia, Canada, the Netherlands, the Philippines, the UAE and the U.S.



The company is preparing for a <a href="https://finance.yahoo.com/news/vivopower-announces-binding-heads-agreement-151900389.html">merger of its subsidiary</a>, Tembo E-LV, with Cactus Acquisition Corp. 1 Limited (NASDAQ:<a href="https://investorplace.com/stock-quotes/cctsw-stock-quote/">CCTSW</a>), a special purpose acquisition company in preparation for taking Tembo public. Tembo, which is an electric vehicle services company in the Netherlands. 



Following the merger, the new Tembo Group expects to be publicly traded on the Nasdaq exchange. The new company would have a valuation of $838 million, with VivoPower shareholders receiving 20% of the company.



Thus, VVPR stock is an interesting bet on EVs with heavy European exposure. VivoPower stock is up 37% this year and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Soligenix (SNGX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/sngx1600-300x169.png" alt="Soligenix is a leading biopharmaceutical firm developing drugs for rare diseases. It's renowned for solutions in oncology biodefense fields. SNGX stock"><div>Source: MacroEcon / Shutterstock.com</div></div>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) is a U.S. biopharmaceutical company that is working on a variety of products. It currently has several drug candidates in advanced stages of trials, including a treatment for early-stage cutaneous T-cell lymphoma in Phase 3 testing.



Soligenix has other Phase 2 tests underway for psoriasis, oral mucositis, and pediatric Crohn&rsquo;s disease.



But it&rsquo;s the early-stage cutaneous T-cell lymphoma trial that has investors excited. The stock jumped nearly 300% earlier this month &ndash; before giving some of those gains back &ndash; following a study testing HyBryte as a treatment). 



Six patients are enrolled in the yearlong study, with four of them completing at least 12 weeks of treatment. Of those, Soligenix says three patients already achieved treatment success, which is a 50% improvement in their cumulative mCAILS score compared to baseline. The fourth patient also saw improvement, the company said.



While this is a positive development, it&rsquo;s important to recognize that HyBryte is still a long way from making it to regulatory approval. But as a speculative play, SNGX stock has potential.



The stock is up 48% in the last month and has a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>First Foundation (FFWM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/05/piggy-bank-grad-300x169.jpg" alt="A pink piggy bank wearing a grad cap sits on a wooden table in front of a chalkboard."><div>Source: Shutterstock</div></div>First Foundation (NYSE:<a href="https://investorplace.com/stock-quotes/ffwm-stock-quote/">FFWM</a>) is a regional bank that&rsquo;s headquartered in Dallas, but has offices in California, Florida, Hawaii, Nevada and Texas.



The bank has $13.6 billion in assets as well as $10.1 billion of loans, deposits of $10.6 billion and stockholder equity of $929 million.



It also just completed an <a href="https://investor.ff-inc.com/news/news-details/2024/First-Foundation-Inc.-Closes-228-Million-Equity-Investment-Anchored-by-Fortress-Investment-Group-Canyon-Partners-Strategic-Value-Bank-Partners-and-North-Reef-Capital/default.aspx">investment deal</a> with several investment firms, including Fortress Investment Group, Canyon Partners, Strategic Value Bank Partners and North Reef Capital that injected $228 million into the company. First Foundation issued 11.3 million shares of stock valued at $4.10 each as part of the transaction.



The company is reporting second-quarter earnings on July 25, with <a href="https://investorplace.com/2024/07/why-is-first-foundation-ffwm-stock-down-27-today/">analysts expecting</a> flat adjusted earnings per share as well as revenue of $54.48 million. A year ago in the second quarter, FFWM saw $61.1 million in revenue and earnings of 7 cents per share.



Regional banking stocks have been challenging investments for the last few quarters, but FFWM appears to be on an upswing. The stock is up 25% in the last month and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://url.us.m.mimecastprotect.com/s/AAadCPNlWWs3yKYns0yRM6?domain=investorplace.com/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/market360/2024/07/7-top-stocks-under-10-july-2024-edition/">7 Top Stocks Under $10: July 2024 Edition</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Top Stocks Under $10: July 2024 Edition

Soligenix GAAP EPS of -$1.31 beats by $0.46

Soligenix (SNGX) announced that the Hong Kong Patent Office has granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin"...

Soligenix granted Hong Kong patent for production of synthetic hypericin

"We remain focused on multiple clinical activities and upcoming milestones, including the initiation of our confirmatory Phase 3 placebo-controlled...

Soligenix reports Q3 EPS (78c) vs. ($2.56) last year

Soligenix GAAP EPS of -$0.78 beats by $0.61

Soligenix (SNGX) has opened patient enrollment for its Phase 2 study evaluating SGX945 – dusquetide – in the treatment of Behcet's Disease. Soligen...

Soligenix initiates Phase 2 clinical trial of SGX945 in Behcet's Disease

Soligenix (SNGX) announced the formation of a European Medical Advisory Board to provide additional medical/clinical strategic guidance to the comp...

Soligenix forms European Medical Advisory Board

Soligenix (SNGX) announced that analysis of the post-treatment data from the open-label study, protocol HPN-CTCL-04, comparing HyBryte to Valchlor ...

Soligenix announces analysis from protocol HPN-CTCL-04

Soligenix (SNGX) announced that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte in the treatment of cutaneou...

Soligenix initiates confirmatory Phase 3 trial of HyBryte

AEHR

AFCG

APDN

CCTSW

CMLS

FFIE

FFWM

KOSS

MRDB

NAAS

SDST

SEEL

SIFY

SMFL

SOUN

STIM

TCJH

VVPR

YYAI

ZAPP

Press Releases

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

Earnings

Small Cap

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Events

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Comments

Soligenix

Soligenix (SNGX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga